Pulmonx (LUNG) Projected to Announce Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is projected to release its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect Pulmonx to post earnings of ($0.28) per share and revenue of $22.3940 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.33). Pulmonx had a negative return on equity of 92.94% and a negative net margin of 60.09%.The company had revenue of $20.59 million for the quarter, compared to analyst estimates of $20.43 million. On average, analysts expect Pulmonx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Trading Down 6.3%

Shares of NASDAQ LUNG opened at $1.27 on Wednesday. Pulmonx has a 12 month low of $1.13 and a 12 month high of $3.88. The company has a market cap of $53.64 million, a price-to-earnings ratio of -0.98 and a beta of 0.30. The company has a quick ratio of 4.04, a current ratio of 4.91 and a debt-to-equity ratio of 0.81. The business has a fifty day simple moving average of $1.43 and a 200-day simple moving average of $1.51.

Hedge Funds Weigh In On Pulmonx

Hedge funds have recently modified their holdings of the stock. Cerity Partners LLC purchased a new stake in shares of Pulmonx during the fourth quarter worth $27,000. Opal Capital LLC acquired a new stake in Pulmonx during the fourth quarter valued at $29,000. Jain Global LLC purchased a new position in Pulmonx in the third quarter valued at about $30,000. Lazard Asset Management LLC purchased a new position in Pulmonx in the fourth quarter valued at about $31,000. Finally, Two Sigma Investments LP grew its stake in Pulmonx by 50.3% in the third quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock valued at $75,000 after purchasing an additional 15,557 shares in the last quarter. 91.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research note on Monday, July 13th. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, D. Boral Capital restated a “buy” rating and set a $14.00 price target on shares of Pulmonx in a report on Thursday, April 30th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pulmonx presently has an average rating of “Hold” and an average target price of $5.58.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.